SOURCE: EastBridge Investment Group

January 23, 2008 08:00 ET

EastBridge Investment Group Obtains 9th Client -- Huang Wei Pharmaceutical Company to Take Public in United States

PHOENIX, AZ--(Marketwire - January 23, 2008) - EastBridge Investment Group (EBIG) (OTCBB: EBIG), today announced that it has signed a definitive listing agreement with Huang Wei Pharmaceutical Company, Hebei, China, to take it public in the United States.

EastBridge will provide listing services to Huang Wei, a well known Chinese pharmaceutical company located approximately two hours from Beijing, with the intent to list the company on the United States stock market as soon as possible. Huang Wei has recently added over thirty drug approvals from the Chinese FDA. Its products range from the special anti-inflammatory to blood pressure-lowering drugs.

Norm Klein, CFO and COO of EBIG, commented, "The Chinese pharmaceutical market in terms of volume is now the world's number one. It is divided into many categories. Huang Wei is a well known producer of drugs for age-related ailments. With the number of new approvals, there is a big potential for Huang Wei to expand and acquire a larger market share. The company itself is profitable and increasing its revenue. We are confident that both shareholders from Huang Wei and EBIG will benefit from this listing project."

EastBridge divides its clients into three annual revenue sizes: Growth: one to ten million dollars; Market-Niche: ten to twenty million dollars; and Market-Leader: above twenty million dollars. Huang Wei is in the high Growth category.

Depending on the complexity and size of each project, EastBridge normally is compensated anywhere from 10-25% stock ownership in the client company for the listing services provided.

EastBridge Investment Group focuses on small to medium-size high-growth companies in China and India offering IPOs, Joint Ventures and Merchant Banking services. The Company targets industries in electronics, real estate, auto, metal, energy, environmental, bioscience and food retail distribution. To learn more about EastBridge Investment Group go to our web site: www.EbigCorp.com. To receive EBIG's email alert, send a blank email to info@EbigCorp.com.

To learn more about EBIG, please listen to the CEO's interview conducted by Killian Brandon, senior analyst of Wall Street Reporter: http://www.wallstreetreporter.com/page.php?page=featured&id=27650

To view an analyst's report by Chris Gupta, CFA, senior equity stock analyst: http://www.ebigcorp.com/EBIG/Home/Ebig_Analysts_Report.pdf

Forward-Looking Statements

Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.

Contact Information

  • Contact:
    Norm Klein
    EastBridge Investment Group Corp.
    480-966-2020
    480-966-0808 (fax)
    Email Contact

    Investor Relations:
    Jack Eversull
    The Eversull Group, Inc.
    972-378-7917
    972-378-7981 (fax)
    Email Contact